Julio Vieira, MD
Neurology · Kingston, NYNPI 1962776138
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $117,790 of the $147,470 with a category attached, or 79.9%. AbbVie accounts for 79.0% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $42,312, more than ten times the $601 reported in 2019. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 358 payments — averaging $411.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$116K
- Biohaven Pharmaceutical Holding Company Ltd.$9K
- Pfizer$7K
- Axsome Therapeutics, Inc.$7K
- Biodelivery Sciences International, Inc.$3K
- Amneal Pharmaceuticals LLC$2K
- plus $3K from 11 others
Across 4 payments — averaging $1352.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$5K
What the payments were for
- Consulting fees$13,0169%
- Speaking & faculty fees$117,79080%
- Travel & lodging$5,9524%
- Food & beverage$10,6747%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 266 | $116,459 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $8,802 |
| Pfizer | 30 | $7,134 |
| Axsome Therapeutics, Inc. | 8 | $6,737 |
| Biodelivery Sciences International, Inc. | 1 | $2,500 |
| Amneal Pharmaceuticals LLC | 2 | $2,456 |
| Lundbeck LLC | 6 | $1,855 |
| Biohaven Pharmaceuticals, Inc. | 7 | $472 |
| Lilly USA, LLC | 11 | $352 |
| Tonix Medicines, Inc. | 7 | $202 |
| Impel Pharmaceuticals Inc. | 2 | $180 |
| Boston Scientific | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $76 |
| Amgen | 2 | $50 |
| Livanova USA, Inc. | 1 | $29 |
| Neuropace, Inc. | 1 | $27 |
| SK Life Science, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$61,131
- BOTOX$38,460
- QULIPTA$29,183
- NURTEC ODT$15,160
- Symbravo$6,522
- ELYXYB - CELECOXIB$2,500
- BREKIYA$2,363
- VYEPTI$1,706
- ZAVZPRET$586
- Trudhesa$141
- GENERAL PAIN MANAGEMENT$125
- EMGALITY$110
How this compares
$147,470 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 108 | $217,855 |
| UbrelvyUbrogepant | 103 | $155,594 |
| Emgality PenGalcanezumab-Gnlm | 87 | $69,696 |
| QuliptaAtogepant | 14 | $18,190 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 17 | $16,279 |
| Ajovy SyringeFremanezumab-Vfrm | 15 | $10,252 |
| Donepezil Hcl | 43 | $2,424 |
| Propranolol Hcl ErPropranolol Hcl | 35 | $1,602 |
| Gabapentin | 74 | $1,571 |
| Tizanidine Hcl | 73 | $1,354 |
| RizatriptanRizatriptan Benzoate | 77 | $1,035 |
| Sumatriptan Succinate | 78 | $946 |
| Topiramate | 82 | $900 |
| Pregabalin | 26 | $823 |
| Levetiracetam | 32 | $812 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $7,134 | $217,855108 claims |
| AbbVieUbrelvy, Qulipta | $116,459 | $173,784117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.
Other neurology in Kingston
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
- Richard LiptonBronx$753K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.